Clinical & Diagnostic
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...
October 15, 2025 | News
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, whic...
October 14, 2025 | News
EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...
October 14, 2025 | News
Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism des...
October 14, 2025 | News
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...
October 13, 2025 | News
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced that it has completed data collection for the primary endpoint in the Phase I...
October 13, 2025 | News
C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...
October 13, 2025 | News
Development agreement applies Optimer® binders to cancer imaging and therapeutics Platform demonstrates versatility across multiple ther...
October 10, 2025 | News
Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed...
October 09, 2025 | News
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury Thermo Fisher Scientific, the world leader in serv...
October 09, 2025 | News
Anasens Inc., a developer of rapid, connected point-of-care detection tools, announced it has signed a distribution agreement with MAVAND Soluti...
October 08, 2025 | News
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced an exclusive collaboration and in-licensing agreem...
October 09, 2025 | News
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement ...
October 07, 2025 | News
Most Read
Bio Jobs
News
Editor Picks